Tenaya Therapeutics and Alnylam Pharmaceuticals have agreed to collaborate on identifying potential new gene therapies for the treatment of cardiovascular disease. Tenaya will receive an upfront payment of $10 million, but stands to earn much more.
Freestanding EDs demonstrated meaningful operational advantages over hospitals when using an accelerated troponin pathway. This included earlier discharges for low-risk chest pain patients.
The AI model showcased an ability to accurately identify signs of pulmonary hypertension in retinal images. "This opens the possibility of using a simple photograph to gain insights into a premature infant's overall health," one researcher explained.
The AI-powered Relief System is able to modulate venous pressure using hemodynamic data. The goal is to help patients better manage heart failure congestion at home.
STS plans on using new research out of Mayo Clinic to help with the development of a surgical risk calculator for adults with this challenging condition.
Their goal is to shape the future of medical imaging, enhance the standard of care, and improve patient outcomes by incorporating advancements in AI and digital solutions.
Researchers evaluated two techniques for predicting PPM after TAVR, comparing them to how cardiologists typically check for PPM in day-to-day practice.
At what looks to be an 18% cost savings downstream, stress echocardiograms looks to be the least expensive diagnostic procedure for patients with chest pain
Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."
Firas Zahr, MD, spoke to Cardiovascular Business about early data on the Medtronic TMVR device. His team's study is designed to follow patients for a total of five years.
